1. Scrip

G1’s Cosela Could Show Promise In Triple-Negative Breast Cancer Despite Colorectal Cancer Fail

Shares Down 51%

 
• By Ayisha Sharma

The US biotech’s myeloprotective drug saw worse responses in a late-stage colorectal cancer trial when compared with placebo but some analysts say other label expansion efforts could fare better.  

Red and blue colon highlighted in illustrated human body
It's The End Of The Road For Cosela In Colorectal Cancer • Source: Shutterstock

G1 Therapeutics Inc. has hit the brakes on metastatic colorectal cancer (mCRC) R&D following a pivotal disappointment for its already-approved lung cancer drug Cosela in the disease, but some analysts still have hope for its potential in other solid tumors.

Cosela (trilaciclib), a first-in-class intravenous myeloprotective therapy, won US approval to reduce the frequency of chemotherapy-induced bone marrow suppression in small cell lung cancer (SCLC) patients back in 2021. G1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D